Saudi SASO Tightens PET Cold Chain Label Rules

On June 1, 2026, the Saudi Standards, Metrology and Quality Organization (SASO) issued SASO IEC 62471:2026 Amendment 2, making low-temperature bend resistance a mandatory requirement for optical PET film used in pharmaceutical cold chain labels. The update deserves attention from medical label film exporters, PET film suppliers, label converters, cold chain logistics participants, and compliance service providers because it directly affects qualification documents, product verification, and export readiness for the Saudi market.

Event Overview

According to the disclosed information, SASO released SASO IEC 62471:2026 Amendment 2 on June 1, 2026. The amendment upgrades the low-temperature tolerance requirement for optical PET film used in pharmaceutical cold chain labels into a mandatory indicator.

The specified requirement is that the film must pass a test involving ten 180-degree bending cycles at -40℃, with no visible cracks. The rule applies to all medical-grade PET label films exported to Saudi Arabia.

The amendment will be fully implemented from September 1, 2026. During the transition period, relevant products must be supported by a third-party low-temperature reliability report.

Which Segments Are Affected

Direct Export and Trade Companies

Exporters shipping medical-grade PET label films to Saudi Arabia are directly affected because the new requirement applies to all such products entering the Saudi market. The main impact is on export documentation and order fulfillment readiness.

Companies handling Saudi-bound shipments need to confirm whether existing products can meet the -40℃ bending requirement and whether third-party low-temperature reliability reports are available during the transition period. If documents are incomplete, shipment schedules and customer delivery commitments may face additional review pressure.

Raw Material Procurement Teams

Procurement teams may be affected because the performance of optical PET film under low-temperature bending conditions becomes a mandatory compliance concern for pharmaceutical cold chain label applications.

From an industry perspective, purchasing decisions may need to place greater emphasis on whether suppliers can provide test evidence aligned with the new requirement. This does not mean every PET film purchase changes immediately, but Saudi-bound medical cold chain label projects will require more careful supplier qualification and material traceability checks.

Label Converting and Processing Manufacturers

Label converters and processing manufacturers are affected because the regulation focuses on the finished label film performance under a specific cold-condition bending test. Even when the base PET film is suitable, converting processes may still need to be reviewed against the required application scenario.

The impact mainly appears in product verification, batch control, and customer communication. Manufacturers serving pharmaceutical cold chain labels for Saudi export should check whether their current production and inspection arrangements can support third-party reliability reporting during the transition period.

Distribution and Channel Operators

Distributors and channel companies supplying PET label films for Saudi-related pharmaceutical cold chain use may face additional requirements from downstream buyers. The reason is that customers may ask for clearer proof of compliance before placing or receiving orders.

What deserves closer attention now is the distinction between general PET label film inventory and medical-grade PET label film intended for Saudi cold chain applications. Channel operators may need to classify stock and avoid mixing products with different compliance status.

Supply Chain and Compliance Service Providers

Testing, certification coordination, documentation review, and logistics support providers may be affected because the transition period requires third-party low-temperature reliability reports.

Analysis shows that service demand may become more focused on test report availability, report applicability, and document matching for Saudi-bound shipments. However, this should be understood as a compliance execution need based on the disclosed amendment, not as evidence of broader market expansion.

What Companies Should Watch and How to Respond

Track Official Follow-up and Implementation Details

Companies should continue monitoring SASO-related official communication regarding the amendment, especially any clarification on report format, accepted testing arrangements, and enforcement procedures before September 1, 2026.

It is more appropriate to understand the current disclosure as a confirmed regulatory update with practical details that still require close operational tracking. Exporters should avoid relying only on internal declarations when third-party low-temperature reliability reports are required during the transition period.

Identify Saudi-Bound Medical PET Label Film Orders

Businesses should separate Saudi-bound medical-grade PET label film projects from ordinary label film business. The amendment specifically concerns optical PET film used for pharmaceutical cold chain labels and exported to Saudi Arabia.

Practical actions include reviewing open orders, pending quotations, product specifications, and customer files to determine which items need evidence for the -40℃, ten-cycle, 180-degree bending test with no visible cracks.

Review Supplier and Test Report Readiness

Procurement and quality teams should confirm whether upstream suppliers can support the new mandatory requirement. During the transition period, the key document is a third-party low-temperature reliability report.

Companies should check whether reports clearly correspond to the relevant medical-grade PET label film and whether the tested condition matches the disclosed requirement. This is more useful than making broad changes to all PET film procurement without distinguishing application and destination market.

Prepare Customer Communication Before Full Enforcement

Because full implementation begins on September 1, 2026, companies should communicate early with Saudi customers, importers, and downstream pharmaceutical cold chain label users. The purpose is to align expectations on compliance evidence, delivery timing, and product qualification status.

Observably, the transition period may create questions around existing inventory, new orders, and report timing. Clear communication can reduce disputes over whether a shipment is covered by the updated requirement and whether supporting documentation is sufficient.

Editor’s View / Industry Observation

Analysis shows that this update is not merely a technical wording change for PET film. For companies involved in Saudi pharmaceutical cold chain label supply, the mandatory -40℃ bending performance requirement turns low-temperature reliability into a direct market access concern.

From an industry perspective, the amendment is already a concrete compliance result because the full enforcement date and transition-period documentation requirement have been disclosed. At the same time, it also functions as a policy signal: product performance evidence and third-party reliability reporting may become more important in Saudi-bound medical label film business.

What deserves closer attention now is not whether low-temperature resistance is generally important, but whether each Saudi-bound medical-grade PET label film product can be matched with the required test evidence before the implementation deadline.

Conclusion

The SASO update gives companies exporting medical-grade optical PET label films to Saudi Arabia a clear compliance checkpoint: the product must withstand ten 180-degree bending cycles at -40℃ without visible cracks, and the rule becomes fully effective on September 1, 2026.

It is more appropriate to understand this development as both a confirmed regulatory requirement and a practical reminder for the supply chain. Exporters, material buyers, label converters, distributors, and compliance service providers should focus on product scope, documentation readiness, and customer communication rather than treating the issue as a general PET film market change.

Information Source Statement

Main source: Saudi Standards, Metrology and Quality Organization (SASO), SASO IEC 62471:2026 Amendment 2, as described in the provided event information.

Items requiring continued observation: any further SASO clarification on implementation procedures, third-party report acceptance, and enforcement practices during and after the transition period.